Gross Profit Summary of Genmab A/S

Genmab A/S's latest annual gross profit in 2023 was 16.24 Billion DKK , up 11.33% from previous year.
Genmab A/S's latest quarterly gross profit in 2024 Q2 was 5.21 Billion DKK , up 31.68% from previous quarter.
Genmab A/S reported a annual gross profit of 14.59 Billion DKK in annual gross profit 2022, up 72.07% from previous year.
Genmab A/S reported a annual gross profit of 8.48 Billion DKK in annual gross profit 2021, down -16.11% from previous year.
Genmab A/S reported a quarterly gross profit of 3.95 Billion DKK for 2024 Q1, down -13.05% from previous quarter.
Genmab A/S reported a quarterly gross profit of 4.55 Billion DKK for 2023 Q4, down -1.98% from previous quarter.

Annual Gross Profit Chart of Genmab A/S (2023 - 2002)

Historical Annual Gross Profit of Genmab A/S (2023 - 2002)

Year	Gross Profit	Gross Profit Growth
2023	16.24 Billion DKK	11.33%
2022	14.59 Billion DKK	72.07%
2021	8.48 Billion DKK	-16.11%
2020	10.11 Billion DKK	88.43%
2019	5.36 Billion DKK	77.38%
2018	3.02 Billion DKK	27.89%
2017	2.36 Billion DKK	30.25%
2016	1.81 Billion DKK	60.29%
2015	1.13 Billion DKK	33.24%
2014	850.38 Million DKK	28.15%
2013	663.57 Million DKK	36.92%
2012	484.63 Million DKK	366.91%
2011	-181.57 Million DKK	-41640.46%
2010	-435 Thousand DKK	-100.07%
2009	586.07 Million DKK	-15.83%
2008	696.3 Million DKK	31.49%
2007	529.53 Million DKK	290.67%
2006	135.54 Million DKK	37.6%
2005	98.5 Million DKK	2301.98%
2004	4.1 Million DKK	-94.0%
2003	68.32 Million DKK	0.0%
2002	- DKK	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	5.21 Billion DKK	31.68%
2024 Q1	3.95 Billion DKK	-13.05%
2023 Q4	4.55 Billion DKK	-1.98%
2023 Q2	4.17 Billion DKK	46.36%
2023 Q1	2.85 Billion DKK	-45.4%
2023 FY	16.24 Billion DKK	11.33%
2023 Q3	4.64 Billion DKK	11.18%
2022 Q3	4.08 Billion DKK	29.25%
2022 Q4	5.22 Billion DKK	27.89%
2022 Q1	2.11 Billion DKK	-19.09%
2022 Q2	3.16 Billion DKK	49.22%
2022 FY	14.59 Billion DKK	72.07%
2021 Q2	1.97 Billion DKK	24.73%
2021 Q1	1.58 Billion DKK	-22.65%
2021 Q4	2.61 Billion DKK	13.38%
2021 Q3	2.31 Billion DKK	17.14%
2021 FY	8.48 Billion DKK	-16.11%
2020 Q1	892 Million DKK	-69.88%
2020 Q3	1.72 Billion DKK	-68.37%
2020 Q4	2.04 Billion DKK	18.56%
2020 FY	10.11 Billion DKK	88.43%
2020 Q2	5.45 Billion DKK	511.1%
2019 FY	5.36 Billion DKK	77.38%
2019 Q4	2.96 Billion DKK	184.78%
2019 Q3	1.03 Billion DKK	34.36%
2019 Q2	773.91 Million DKK	30.95%
2019 Q1	591 Million DKK	-52.18%
2018 Q2	509.67 Million DKK	-25.16%
2018 FY	3.02 Billion DKK	27.89%
2018 Q4	1.23 Billion DKK	106.46%
2018 Q3	598.59 Million DKK	17.45%
2018 Q1	681.01 Million DKK	-33.09%
2017 FY	2.36 Billion DKK	30.25%
2017 Q2	773.34 Million DKK	208.38%
2017 Q4	1.01 Billion DKK	214.69%
2017 Q3	323.44 Million DKK	-58.18%
2017 Q1	250.77 Million DKK	-72.96%
2016 Q2	353.82 Million DKK	107.92%
2016 FY	1.81 Billion DKK	60.29%
2016 Q1	170.17 Million DKK	-70.39%
2016 Q3	364.66 Million DKK	3.06%
2016 Q4	927.46 Million DKK	154.33%
2015 Q4	574.65 Million DKK	106.89%
2015 Q2	173.84 Million DKK	62.81%
2015 Q3	277.76 Million DKK	59.78%
2015 FY	1.13 Billion DKK	33.24%
2015 Q1	106.77 Million DKK	-50.52%
2014 Q1	247.07 Million DKK	14.36%
2014 FY	850.38 Million DKK	28.15%
2014 Q4	215.8 Million DKK	-20.52%
2014 Q3	271.52 Million DKK	134.09%
2014 Q2	115.98 Million DKK	-53.06%
2013 Q2	138.09 Million DKK	-13.57%
2013 Q1	159.77 Million DKK	-2.04%
2013 Q4	216.04 Million DKK	44.35%
2013 FY	663.57 Million DKK	36.92%
2013 Q3	149.66 Million DKK	8.38%
2012 Q1	-29.04 Million DKK	40.89%
2012 Q2	-21.15 Million DKK	27.17%
2012 Q3	115.87 Million DKK	647.83%
2012 Q4	163.1 Million DKK	40.76%
2012 FY	484.63 Million DKK	366.91%
2011 Q1	-44.35 Million DKK	22.46%
2011 Q2	-47.66 Million DKK	-7.47%
2011 Q4	-49.13 Million DKK	-21.55%
2011 FY	-181.57 Million DKK	-41640.46%
2011 Q3	-40.41 Million DKK	15.21%
2010 Q1	-113.68 Million DKK	-158.93%
2010 FY	-435 Thousand DKK	-100.07%
2010 Q3	193.71 Million DKK	932.7%
2010 Q4	-57.2 Million DKK	-129.53%
2010 Q2	-23.26 Million DKK	79.54%
2009 Q2	74.17 Million DKK	-70.33%
2009 FY	586.07 Million DKK	-15.83%
2009 Q1	249.98 Million DKK	0.0%
2009 Q4	192.89 Million DKK	278.77%
2009 Q3	-107.9 Million DKK	-245.48%
2008 FY	696.3 Million DKK	31.49%
2007 FY	529.53 Million DKK	290.67%
2006 FY	135.54 Million DKK	37.6%
2005 FY	98.5 Million DKK	2301.98%
2004 FY	4.1 Million DKK	-94.0%
2003 FY	68.32 Million DKK	0.0%
2002 FY	- DKK	0.0%

Peer Gross Profit Comparison of Genmab A/S

Name	Gross Profit	Gross Profit Difference
ALK-Abelló A/S	3.03 Billion DKK	-435.354%
Bavarian Nordic A/S	4.52 Billion DKK	-259.33%
Gubra A/S	114.93 Million DKK	-14036.563%
Novo Nordisk A/S	196.49 Billion DKK	91.731%
Orphazyme A/S	- DKK	-Infinity%
Pharma Equity Group A/S	-480 Thousand DKK	3385100.0%
Zealand Pharma A/S	323.61 Million DKK	-4920.796%

Global Stocks Search

Genmab A/S (GMAB.CO)

Gross Profit Summary of Genmab A/S

Annual Gross Profit Chart of Genmab A/S (2023 - 2002)

Historical Annual Gross Profit of Genmab A/S (2023 - 2002)

Peer Gross Profit Comparison of Genmab A/S